TOKYO -- Japanese pharmaceutical group Eisai has essentially given up on a prospective blockbuster Alzheimer's disease drug and will instead focus resources on developing a follow-up offering.
Pharmaceuticals
Eisai reboots search for blockbuster Alzheimer's drug
Failure to strike gold with Aduhelm prompts renewed focus on successor
